Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 2 3Phase 3 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1Neoplasms 1Nausea 1Breast Neoplasms 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Standard of Care 3Oxaliplatin 3Melatonin 3Gemcitabine 3Fluorouracil 3Drug Therapy 3Ciprofloxacin 3Capecitabine 3pertuzumab 2entrectinib 2cobimetinib 2capmatinib 2atezolizumab 2alectinib 2Water 2Vemurafenib 2Trastuzumab 2Sirolimus 2Saline Solution 2Pemetrexed 2Methylphenidate 2Lidocaine 2Leucovorin 2Immunoglobulins, Intravenous 2Docetaxel 2Dexmedetomidine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasms × Palonosetron × Clear all
NCT03040726 2023-10-17

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

M.D. Anderson Cancer Center

Phase 2/3 Completed
53 enrolled 15 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡